Integrated Traditional Chinese and Western Medicine in Lung Adenocarcinoma with Rare EGFR Mutation and Nephrotic Syndrome: A Case Report
Gespeichert in:
| Titel: | Integrated Traditional Chinese and Western Medicine in Lung Adenocarcinoma with Rare EGFR Mutation and Nephrotic Syndrome: A Case Report |
|---|---|
| Autoren: | Lirong Zhang, Liye Cai, Luwei Ruan, Jie Li |
| Quelle: | Cancer Manag Res Cancer Management and Research, Vol Volume 17, Iss Issue 1, Pp 1293-1299 (2025) |
| Verlagsinformationen: | Informa UK Limited, 2025. |
| Publikationsjahr: | 2025 |
| Schlagwörter: | malignant pleural effusion, Nephrotic syndrome, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, Endostar, Case Report, EGFR mutation, lung adenocarcinoma, RC254-282, albumin-bound paclitaxel |
| Beschreibung: | This case report presents a 67-year-old male diagnosed with stage IV lung adenocarcinoma harboring rare EGFR exon 18/20 mutations (Gly719Cys/Ser768Ile) and a concurrent TP53 mutation, complicated by nephrotic syndrome. The scarcity of approved EGFR-TKIs targeting rare EGFR mutations in NSCLC, coupled with nephrotic syndrome-induced renal impairment, hypoalbuminemia, and massive pleural effusion refractory to conventional management, prompted the development of a personalized multimodal approach.A multimodal therapeutic regimen incorporating albumin-bound paclitaxel, intrathoracic perfusion of Endostar (recombinant human endostatin), and traditional Chinese medicine (TCM) was implemented, achieving effective disease control. Notably, the treatment resulted in significant tumor shrinkage (reduction rate: 48.1% by RECIST 1.1), complete resolution of malignant pleural effusion, and marked improvement in nephrotic syndrome parameters. The synergistic effects of targeted chemotherapy, anti-angiogenic therapy, and TCM-based symptom modulation highlight the potential of integrative approaches in managing advanced malignancies with complex molecular profiles and multisystem complications. |
| Publikationsart: | Article Other literature type |
| Sprache: | English |
| ISSN: | 1179-1322 |
| DOI: | 10.2147/cmar.s526571 |
| Zugangs-URL: | https://doaj.org/article/ba7c041c7d1d473e918835af26a1e0a7 |
| Rights: | CC BY NC URL: http://creativecommons.org/licenses/by-nc/4.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at http://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v4.0) License (http://creativecommons.org/licenses/by-nc/4.0/ (http://creativecommons.org/licenses/by-nc/4.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (http://www.dovepress.com/terms.php). |
| Dokumentencode: | edsair.doi.dedup.....9b6b45db4c2a142c5dba94e7bcdc94fa |
| Datenbank: | OpenAIRE |
Full Text 
Full Text Finder 
Nájsť tento článok vo Web of Science | Abstract: | This case report presents a 67-year-old male diagnosed with stage IV lung adenocarcinoma harboring rare EGFR exon 18/20 mutations (Gly719Cys/Ser768Ile) and a concurrent TP53 mutation, complicated by nephrotic syndrome. The scarcity of approved EGFR-TKIs targeting rare EGFR mutations in NSCLC, coupled with nephrotic syndrome-induced renal impairment, hypoalbuminemia, and massive pleural effusion refractory to conventional management, prompted the development of a personalized multimodal approach.A multimodal therapeutic regimen incorporating albumin-bound paclitaxel, intrathoracic perfusion of Endostar (recombinant human endostatin), and traditional Chinese medicine (TCM) was implemented, achieving effective disease control. Notably, the treatment resulted in significant tumor shrinkage (reduction rate: 48.1% by RECIST 1.1), complete resolution of malignant pleural effusion, and marked improvement in nephrotic syndrome parameters. The synergistic effects of targeted chemotherapy, anti-angiogenic therapy, and TCM-based symptom modulation highlight the potential of integrative approaches in managing advanced malignancies with complex molecular profiles and multisystem complications. |
|---|---|
| ISSN: | 11791322 |
| DOI: | 10.2147/cmar.s526571 |